If I had $10,000 to put to work in ASX 200 shares this February, I wouldn’t overthink it. I’d focus on a small group of high-quality businesses with strong earnings, clear long-term drivers, and the ability to ride out whatever the market throws at them this year.
This isn’t about finding the next hot stock. It’s about stacking the odds in favour of sensible, long-term returns.
Here’s where my money would go.
CSL Ltd (ASX: CSL)
After a difficult period marked by slower plasma margin recovery, softer albumin demand in China, and weakness in influenza vaccines, expectations around CSL are far more realistic than they were a few years ago. What hasn’t changed is the quality of the business.
CSL remains a global leader in plasma therapies, operating in an oligopolistic market with very high barriers to entry. Demand for immunoglobulins continues to grow structurally, and efficiency initiatives should support margins over time. For a long-term investor, I think the risk-reward looks far more balanced than it did near the top of the cycle.
ResMed Inc (ASX: RMD)
ResMed is another ASX 200 name I’d be very comfortable buying with the $10,000. The medical device company continues to deliver strong revenue growth, improving margins, and expanding cash flow, driven by rising awareness and diagnosis of sleep apnoea globally. Its software and digital health ecosystem also adds a layer of recurring revenue that many other companies lack.
ResMed doesn’t need a perfect economic backdrop to grow. Its products address chronic conditions, which gives earnings a degree of defensiveness alongside genuine long-term growth.
Wesfarmers Ltd (ASX: WES)
I see Wesfarmers as a capital allocation story. Bunnings and Kmart generate strong cash flows, which management can reinvest into new growth areas or return to shareholders. Over time, that discipline tends to compound quietly.
It’s not a stock that will double overnight. But as part of a $10,000 portfolio, this ASX 200 share offers stability, optionality, and a history of sensible decision-making.
Goodman Group (ASX: GMG)
Goodman Group gives exposure to a different growth theme altogether. It sits at the heart of logistics, urban infill, and data centre infrastructure. Demand for high-quality industrial space remains strong, and its development pipeline continues to grow alongside global data and e-commerce needs.
While interest rates and valuations can create short-term noise, the long-term demand for the assets that this ASX 200 share builds and owns looks very robust to me.
HUB24 Ltd (ASX: HUB)
HUB24 continues to take market share in the Australian wealth platform space, supported by strong adviser adoption and rising funds under administration. Its platform model provides operating leverage, which means earnings can grow faster than revenue as scale increases.
It’s not the cheapest share on the ASX 200, but high-quality platform businesses rarely are. What matters is execution, and HUB24 has been delivering consistently. This is evident in its recent quarterly update.
Foolish takeaway
If I were investing $10,000 in ASX 200 shares this February, I’d spread it across a mix of global leaders, structural growers, and dependable compounders.
Each of my picks in this article brings something different to the table. But together, they create a portfolio that I think could hold up well in the short term and compound nicely over the long run.
The post Where I would invest $10,000 in ASX 200 shares in February appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you buy CSL shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 Jan 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Argo Investments reports record profit and dividend
- Is this the right time to invest in ASX defensive shares?
- Experts name NAB and these ASX 200 shares as sells
- Earnings preview: How do experts rate these blue-chip ASX stocks reporting this week?
- Top brokers name 3 ASX shares to buy next week
Motley Fool contributor Grace Alvino has positions in CSL, Hub24, and Wesfarmers. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goodman Group, Hub24, ResMed, and Wesfarmers. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Goodman Group, Hub24, and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.